Glycoprotein IIb/IIIa inhibitors: Difference between revisions
m Protected "Glycoprotein IIb/IIIa inhibitors": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
mNo edit summary |
||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
'''Associate Editor-In-Chief:''' {{CZ | {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}} | ||
==Overview== | ==Overview== | ||
| Line 16: | Line 12: | ||
*[[Tirofiban]] (Aggrastat<sup>®</sup>) | *[[Tirofiban]] (Aggrastat<sup>®</sup>) | ||
== | ==Indications== | ||
Glycoprotein IIb/IIIa inhibitors are frequently used during percutaneous coronary interventions ([[angioplasty]] with or without intracoronary stent placement). | Glycoprotein IIb/IIIa inhibitors are frequently used during percutaneous coronary interventions ([[angioplasty]] with or without intracoronary stent placement). | ||
| Line 27: | Line 23: | ||
==Reference== | ==Reference== | ||
{{reflist|2}} | |||
==Additional Resources== | ==Additional Resources== | ||
| Line 38: | Line 34: | ||
[[Category:gpIIb/IIIa inhibitors]] | [[Category:gpIIb/IIIa inhibitors]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
{{SIB}} | |||
[[Category:Drug]] | |||
[[Category:Cardiology]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 08:02, 11 December 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Glycoprotein IIb/IIIa inhibitors, also GpIIb/IIIa inhibitors, are a class of antiplatelet agents.
Several GpIIb/IIIa inhibitors exist:
- Abciximab (ReoPro®)
- Eptifibatide (Integrilin®)
- Tirofiban (Aggrastat®)
Indications
Glycoprotein IIb/IIIa inhibitors are frequently used during percutaneous coronary interventions (angioplasty with or without intracoronary stent placement).
They work by preventing platelet aggregation and thrombus formation. They do so by inhibition of the GpIIb/IIIa receptor on the surface of the platelets. By blocking the GPIIbIIIa receptor, they block the ability of platelets to cross link via fibrinogen.
The agents in this class are administered intravenously. Oral forms of these agents were associated with increased mortality, possibly due to underdosing of the agents.
History
Their development arose from the understanding of Glanzmann's thrombasthenia, a condition in which the GpIIb/IIIa is lacking.[1]
Reference
- ↑ Seligsohn U. Glanzmann thrombasthenia: a model disease which paved the way to powerful therapeutic agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):216-7. PMID 13679645. Free Full Text.
Additional Resources
- The MD TV: Comments on Hot Topics, State of the Art Presentations in Cardiovascular Medicine, Expert Reviews on Cardiovascular Research
- Clinical Trial Results: An up to dated resource of Glycoprotein IIb/IIIa inhibitors related clinical trials